As filed with the Securities and Exchange Commission on October 20, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
FATE THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 65-1311552 | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
| 12278 Scripps Summit Drive San Diego, CA |
92131 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
FATE THERAPEUTICS, INC. AMENDED AND RESTATED INDUCEMENT EQUITY PLAN
(Full title of the plan)
Bahram Valamehr, Ph.D., M.B.A.
President and Chief Executive Officer
Fate Therapeutics, Inc.
12278 Scripps Summit Drive
San Diego, CA 92131
(Name and address of agent for service)
(858) 875-1800
(Telephone number, including area code, of agent for service)
Copies to:
| Kingsley L. Taft, Esq. Maggie L. Wong, Esq. Natalie T. Martirossian, Esq. Goodwin Procter LLP 525 Market Street San Francisco, CA 94105 Telephone: (415) 733-6000 |
Cindy R. Tahl, Esq. Chief Legal and Compliance Officer, and Corporate Secretary Fate Therapeutics, Inc. 12278 Scripps Summit Drive San Diego, CA 92131 Telephone: (858) 875-1800 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
| Emerging growth company | ☐ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
On May 10, 2016, the Board of Directors (the “Board”) of Fate Therapeutics, Inc. (the “Company”) adopted the Fate Therapeutics, Inc. Inducement Equity Plan, and on December 17, 2020, the Board amended and restated such plan pursuant to the Fate Therapeutics, Inc. Amended and Restated Inducement Equity Plan (as amended and restated, the “Inducement Plan”). The Inducement Plan was adopted and/or amended and restated without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4).
A total of 500,000 shares of common stock, par value $0.001 per share, of the Company (“Common Stock”), were initially reserved for issuance under the Inducement Plan. On February 12, 2021, February 20-21, 2020, and January 14, 2019, the Board approved an increase of an additional 300,000 shares, 470,822 shares, and 200,000 shares of Common Stock, respectively, to the reserve under the Inducement Plan. Each such increase was adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4).
On October 13, 2025, the Board approved an increase of an additional 1,750,000 shares to the reserve under the Inducement Plan. This increase was adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4).
The only persons eligible to receive grants of Inducement Awards (as defined below) under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Listing Rule 5635(c)(4). An “Inducement Award” means any right to receive Common Stock, cash or other property granted under the Inducement Plan (including nonqualified stock options, restricted stock unit awards, or other stock-based awards).
The Company is filing this registration statement on Form S-8 (this “Registration Statement”) solely for the purpose of registering the 1,750,000 additional shares of Common Stock authorized for issuance under the Inducement Plan. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also includes an indeterminate number of additional shares of Common Stock that may become issuable under the Inducement Plan by reason of anti-dilution and other adjustments.
REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E
Pursuant to General Instruction E of Form S-8, the Company is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register an additional 1,750,000 shares of its Common Stock under the Inducement Plan. Such additional shares are of the same class as other securities for which a registration statement relating to the Inducement Plan has previously been filed and is effective. Pursuant to General Instruction E of Form S-8 regarding Registration of Additional Securities, the contents of the Company’s Registration Statement on Form S-8 (File No. 333-253459), filed with the Commission on February 24, 2021, are hereby incorporated by reference.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
| * | Filed herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on this 20th day of October, 2025.
| FATE THERAPEUTICS, INC. | ||
| By: | /s/ Bahram Valamehr | |
| Bahram Valamehr, Ph.D., M.B.A. | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby severally constitutes and appoints each of Bahram Valamehr, Ph.D., M.B.A. and Kamal Adawi, M.S., M.B.A., and each of them singly, as such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign any or all amendments (including, without limitation, post-effective amendments) to this registration statement (or any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature |
Title |
Date | ||
| /s/ Bahram Valamehr Bahram Valamehr, Ph.D., M.B.A. |
President, Chief Executive Officer and Director (Principal Executive Officer) | October 20, 2025 | ||
| /s/ William H. Rastetter William H. Rastetter, Ph.D. |
Chairman of the Board and Director | October 20, 2025 | ||
| /s/ Matthew C. Abernethy Matthew C. Abernethy, M.B.A. |
Director | October 20, 2025 | ||
| /s/ Michael Lee Michael Lee |
Director | October 20, 2025 | ||
| /s/ Robert S. Epstein Robert S. Epstein, M.D., M.S. |
Director | October 20, 2025 | ||
| /s/ Karin Jooss Karin Jooss, Ph.D. |
Director | October 20, 2025 | ||
| /s/ Shefali Agarwal Shefali Agarwal, M.D. |
Director | October 20, 2025 | ||
| /s/ Yuan Xu Yuan Xu, Ph.D. |
Director | October 20, 2025 | ||
| /s/ Kamal Adawi Kamal Adawi, M.S., M.B.A. |
Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) |
October 20, 2025 | ||